hemophagocytic lymphohistiocytosis
Conditions
Interventions
Study group:Ruxolitinib combined with dexamethasone(Ru-D regimen):
The Ru-D regimen consists of ruxolitinib (15 mg twice daily for 8 weeks) and dexamethasone (initially 10 mg/m2 for 2 weeks followed b
Control froup:HLH-1994 regimen consists of Etoposide (150 mg/m2 twice every week in the first 2 weeks, and weekly in the rest weeks) and dexamethasone (initially 10 mg/m2 for 2 weeks followed by 5 mg/
Sponsors
The first affiliated hospital Zhejiang University school of medicine
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Meet the diagnostic criteria of HLH-2004 2. Age =18 years old 3. Did not receive an HLH regimen containing etoposide 4. Understand the study and sign the informed consent 5. Men, women of childbearing age (postmenopausal women who must have been at least 12 months past menopause to be considered infertile), and their partners voluntarily used contraception deemed effective by the investigators during treatment and for at least three months after the last time they took the study drug
Exclusion criteria
Exclusion criteria: 1. Known central nervous system involvement 2. Known HIV infection 3. Patients with severe renal dysfunction (glomerular filtration rate 20) 5. Known history of active tumor 6. Pregnant or lactating women 7. Inability to understand or follow research protocols
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| overall survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| overall survival rate;complete remission rate;partial remission rate;Improvement in measures of HLH;Progression-free survival;The time to remission;Change trend of related biological indicators;safety; | — |
Countries
China
Contacts
Public ContactHongyan Tong
The first affiliated hospital Zhejiang University school of medicine
Outcome results
None listed